Complement-Targeted Therapy to Restrict Glaucoma Progression

About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
July 01, 2019 - June 30, 2022
Grant ID
G2019219
Acknowledgement
Goals
Glaucoma is a disease that degrades vision over time. In the retina, neurons decline and die, despite the immune responses of supporting glial cells. We have developed a new potential treatment that rebalances immune responses and controls glaucoma in old mice, and will define if it may cure patients by treating several experimental models. Also, we will study how dying or surviving neurons interact with glia in the retina.
Summary
This project will determine whether rebalancing immune activation of complement proteins and microglia via ocular gene therapy is neuroprotective in diverse experimental models of adult-onset glaucoma. Progressive vision loss in glaucoma is the result of gradual neuron decline and death in the retina, which is accompanied by dysregulated glial immune responses. My research focuses on understanding the role and function of microglia in glaucoma, and on developing translatable therapeutic strategies by modulating the actions of microglia.
Grants
Related Grants
National Glaucoma Research
Saving Sight: A Journey to Healing Without Scars
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Jennifer Fan Gaskin, MBChB, MD, FRANZCO
Current Organization
Centre for Eye Research Australia (Australia)
National Glaucoma Research
Retinal Ganglion Cell Axon Degeneration in a 3D Microfluidic Hydrogel Model
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Shruti Patil, PhD
Current Organization
Indiana University School of Medicine
National Glaucoma Research
An Optimal Form of Nerve Growth Factor as a New Neuroprotective Drug for Glaucoma
Active Dates
July 01, 2023 - June 30, 2025

Principal Investigator
Silvia Marinelli, PhD
Current Organization
European Brain Research Institute (Italy)